A patient with nasopharyngeal carcinoma developed multisystem immune-related adverse events (high fever, rash, interstitial pulmonary edema, multiple organ failure) after sintilimab combined with thymosin alpha‑1.
In plain wordsOne patient with nasopharyngeal cancer had severe immune side effects after treatment with sintilimab together with thymosin alpha‑1.
- Peptide
- Thymosin alpha-1
- Outcome
- Not applicableMultisystem immune-related adverse events
- Study
n = 1
- Outcome group
- Adverse events · Immune and inflammation
Source sentences
To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab (PD-1 inhibitor) in combination with thymosin alpha-1 (Tα1).
1 context sentence(design, population, supporting numbers)
The patient presents with high fever, rash, interstitial pulmonary edema, and multiple organ failure.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.